NCT05813314View on ClinicalTrials.gov

Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

June 14, 2023

Study Completion Date

June 14, 2023

Conditions
Achondroplasia
Interventions
COMBINATION_PRODUCT

BMN 111 administration via Injector Pen

BMN 111 Injection will be given using an injector pen

DRUG

BMN 111 administration via vial and syringe

BMN 111 Injection will be given using vial and syringe

Trial Locations (1)

75230

Labcorp, Dallas

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY